PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis

NYSE:MD • US58502B1061

20.06 USD
+0.32 (+1.62%)
At close: Feb 24, 2026
20.06 USD
0 (0%)
After Hours: 2/24/2026, 8:04:00 PM
Fundamental Rating

6

MD gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. MD has an excellent profitability rating, but there are some minor concerns on its financial health. MD is valued quite cheap, while showing a decent growth score. This is a good combination! This makes MD very considerable for value investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • MD had positive earnings in the past year.
  • In the past year MD had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
  • In the past 5 years MD always reported a positive cash flow from operatings.
MD Yearly Net Income VS EBIT VS OCF VS FCFMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B

1.2 Ratios

  • The Return On Assets of MD (7.36%) is better than 90.10% of its industry peers.
  • Looking at the Return On Equity, with a value of 19.10%, MD belongs to the top of the industry, outperforming 86.14% of the companies in the same industry.
  • MD's Return On Invested Capital of 9.88% is amongst the best of the industry. MD outperforms 80.20% of its industry peers.
  • MD had an Average Return On Invested Capital over the past 3 years of 8.21%. This is in line with the industry average of 8.93%.
  • The last Return On Invested Capital (9.88%) for MD is above the 3 year average (8.21%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.36%
ROE 19.1%
ROIC 9.88%
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
MD Yearly ROA, ROE, ROICMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80 -100

1.3 Margins

  • With an excellent Profit Margin value of 8.64%, MD belongs to the best of the industry, outperforming 91.09% of the companies in the same industry.
  • MD's Profit Margin has improved in the last couple of years.
  • MD's Operating Margin of 12.07% is amongst the best of the industry. MD outperforms 83.17% of its industry peers.
  • In the last couple of years the Operating Margin of MD has grown nicely.
Industry RankSector Rank
OM 12.07%
PM (TTM) 8.64%
GM N/A
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MD Yearly Profit, Operating, Gross MarginsMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

6

2. Health

2.1 Basic Checks

  • MD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, MD has less shares outstanding
  • Compared to 5 years ago, MD has less shares outstanding
  • MD has a better debt/assets ratio than last year.
MD Yearly Shares OutstandingMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
MD Yearly Total Debt VS Total AssetsMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

  • MD has an Altman-Z score of 2.05. This is not the best score and indicates that MD is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of MD (2.05) is comparable to the rest of the industry.
  • The Debt to FCF ratio of MD is 2.36, which is a good value as it means it would take MD, 2.36 years of fcf income to pay off all of its debts.
  • MD's Debt to FCF ratio of 2.36 is fine compared to the rest of the industry. MD outperforms 75.25% of its industry peers.
  • MD has a Debt/Equity ratio of 0.66. This is a neutral value indicating MD is somewhat dependend on debt financing.
  • MD's Debt to Equity ratio of 0.66 is in line compared to the rest of the industry. MD outperforms 56.44% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for MD, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 2.36
Altman-Z 2.05
ROIC/WACC1.24
WACC7.99%
MD Yearly LT Debt VS Equity VS FCFMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • MD has a Current Ratio of 1.66. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of MD (1.66) is better than 65.35% of its industry peers.
  • MD has a Quick Ratio of 1.66. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.66, MD is in the better half of the industry, outperforming 69.31% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
MD Yearly Current Assets VS Current LiabilitesMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

4

3. Growth

3.1 Past

  • MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.24%, which is quite impressive.
  • MD shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.01% yearly.
  • The Revenue has decreased by -4.92% in the past year.
  • MD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.99% yearly.
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%

3.2 Future

  • MD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.48% yearly.
  • The Revenue is expected to grow by 4.60% on average over the next years.
EPS Next Y10.99%
EPS Next 2Y8.08%
EPS Next 3Y2.62%
EPS Next 5Y1.48%
Revenue Next Year2.7%
Revenue Next 2Y2.49%
Revenue Next 3Y4.56%
Revenue Next 5Y4.6%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MD Yearly Revenue VS EstimatesMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B
MD Yearly EPS VS EstimatesMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3 4

8

4. Valuation

4.1 Price/Earnings Ratio

  • MD is valuated reasonably with a Price/Earnings ratio of 9.88.
  • Compared to the rest of the industry, the Price/Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 93.07% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of MD to the average of the S&P500 Index (26.98), we can say MD is valued rather cheaply.
  • The Price/Forward Earnings ratio is 8.90, which indicates a very decent valuation of MD.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 93.07% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.01, MD is valued rather cheaply.
Industry RankSector Rank
PE 9.88
Fwd PE 8.9
MD Price Earnings VS Forward Price EarningsMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MD indicates a rather cheap valuation: MD is cheaper than 87.13% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of MD indicates a rather cheap valuation: MD is cheaper than 90.10% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 6.82
EV/EBITDA 6.71
MD Per share dataMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • MD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of MD may justify a higher PE ratio.
PEG (NY)0.9
PEG (5Y)0.99
EPS Next 2Y8.08%
EPS Next 3Y2.62%

0

5. Dividend

5.1 Amount

  • MD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

PEDIATRIX MEDICAL GROUP INC

NYSE:MD (2/24/2026, 8:04:00 PM)

After market: 20.06 0 (0%)

20.06

+0.32 (+1.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-19
Earnings (Next)05-04
Inst Owners98.9%
Inst Owner Change0.65%
Ins Owners1.87%
Ins Owner Change-1.02%
Market Cap1.72B
Revenue(TTM)1.91B
Net Income(TTM)165.39M
Analysts78.67
Price Target21.93 (9.32%)
Short Float %3.33%
Short Ratio4.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.87%
Min EPS beat(2)-9.94%
Max EPS beat(2)39.68%
EPS beat(4)3
Avg EPS beat(4)20.9%
Min EPS beat(4)-9.94%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)17.99%
EPS beat(12)7
Avg EPS beat(12)8.59%
EPS beat(16)8
Avg EPS beat(16)5.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.49%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)0.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-1.43%
Revenue beat(12)2
Avg Revenue beat(12)-2.28%
Revenue beat(16)2
Avg Revenue beat(16)-2.52%
PT rev (1m)0%
PT rev (3m)35.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3%
EPS NY rev (1m)0%
EPS NY rev (3m)16.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.13%
Valuation
Industry RankSector Rank
PE 9.88
Fwd PE 8.9
P/S 0.9
P/FCF 6.82
P/OCF 6.35
P/B 1.99
P/tB N/A
EV/EBITDA 6.71
EPS(TTM)2.03
EY10.12%
EPS(NY)2.25
Fwd EY11.23%
FCF(TTM)2.94
FCFY14.66%
OCF(TTM)3.16
OCFY15.74%
SpS22.29
BVpS10.08
TBVpS-4.79
PEG (NY)0.9
PEG (5Y)0.99
Graham Number21.46
Profitability
Industry RankSector Rank
ROA 7.36%
ROE 19.1%
ROCE 12.93%
ROIC 9.88%
ROICexc 13.71%
ROICexgc 1686.9%
OM 12.07%
PM (TTM) 8.64%
GM N/A
FCFM 13.2%
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
ROICexc(3y)10.42%
ROICexc(5y)9.77%
ROICexgc(3y)618.91%
ROICexgc(5y)394.62%
ROCE(3y)10.75%
ROCE(5y)10.43%
ROICexgc growth 3Y208.98%
ROICexgc growth 5Y85.34%
ROICexc growth 3Y17.7%
ROICexc growth 5Y11.82%
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 2.36
Debt/EBITDA 2.26
Cap/Depr 84.57%
Cap/Sales 0.96%
Interest Coverage 6.72
Cash Conversion 107.19%
Profit Quality 152.75%
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z 2.05
F-Score8
WACC7.99%
ROIC/WACC1.24
Cap/Depr(3y)81.68%
Cap/Depr(5y)85.74%
Cap/Sales(3y)1.24%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
EPS Next Y10.99%
EPS Next 2Y8.08%
EPS Next 3Y2.62%
EPS Next 5Y1.48%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
Revenue Next Year2.7%
Revenue Next 2Y2.49%
Revenue Next 3Y4.56%
Revenue Next 5Y4.6%
EBIT growth 1Y25.81%
EBIT growth 3Y4.93%
EBIT growth 5Y6.1%
EBIT Next Year16.32%
EBIT Next 3Y7%
EBIT Next 5YN/A
FCF growth 1Y36.89%
FCF growth 3Y22.56%
FCF growth 5Y7.52%
OCF growth 1Y31.23%
OCF growth 3Y17.54%
OCF growth 5Y5.79%

PEDIATRIX MEDICAL GROUP INC / MD FAQ

What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?

ChartMill assigns a fundamental rating of 6 / 10 to MD.


What is the valuation status for MD stock?

ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.


How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?

PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 7 / 10.


What are the PE and PB ratios of PEDIATRIX MEDICAL GROUP INC (MD) stock?

The Price/Earnings (PE) ratio for PEDIATRIX MEDICAL GROUP INC (MD) is 9.88 and the Price/Book (PB) ratio is 1.99.